Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

Status: open

16-207 - [923977-5] Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)

Treatment for Breast Cancer

Contact Us Or call (251) 445-9834

Description

The purpose of this study is to assess the effect of tucatinib vs. placebo in combination with capecitabine and trastuzumab on progression-free survival (PFS) per RECIST 1.1 based on independent central review. IRB Number 16-207

Sponsors

This trial is sponsored by Cascadian Therapeutics.

Providers Associated With This Trial

Sub Investigators

This link will open in a new tab or window.